Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever
04:15am, Friday, 08'th Nov 2024
You'll also like these stocks for their track record of earnings growth.
My Top 10 High Dividend Yield Companies For November 2024: 2 Yield More Than 8%
06:00pm, Thursday, 07'th Nov 2024
I will highlight 10 high dividend yield companies which, I believe, are worth considering investing in for November 2024. Each company could increase your portfolio's ability to generate dividend inco
US FDA approves Johnson & Johnson's device for heart condition
08:19am, Thursday, 07'th Nov 2024
The U.S. Food & Drug Administration has approved Johnson & Johnson's device for a type of heart condition, the company said on Thursday.
Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024
08:00am, Thursday, 07'th Nov 2024
New data for investigational nipocalimab in Sjögren's Disease (SjD) and new research on the impact of TREMFYA® (guselkumab) in psoriatic arthritis (PsA) will be highlighted across three oral session
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
10:05am, Tuesday, 05'th Nov 2024
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
2 Great Dividend Aristocrats to Buy in November
08:40am, Tuesday, 05'th Nov 2024
Dividend Aristocrats represent a wide range of stocks in different industries, but each of these companies holds one characteristic in common: their management teams have raised their dividend distrib
Buy 3 November Dogs Of The Dow And Watch 7 More
04:19am, Saturday, 02'nd Nov 2024
"The Dow® [adds a stock] if the company has an excellent reputation,
TAIPEI and SAN DIEGO , Nov. 1, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectiou
4 Safe Dividend Kings Will Deliver Big Passive Income Regardless of the Election Results
11:47am, Wednesday, 30'th Oct 2024
24/7 Wall St. Insights This election could be one of the closest in our history.
A greater number of patients treated with subcutaneous TREMFYA® induction and maintenance achieved clinical and endoscopic remission at 48 weeks in the Phase 3 GRAVITI study versus placebo TREMFYA ®
If I Could Own Only 4 Stocks In Retirement, It Would Be These
07:15am, Monday, 28'th Oct 2024
For retirees, I advise to own high-quality assets that balance growth, income, and stability. My preferred asset allocation includes 70% in equities and dividend-focused ETFs, 20% in short-duration fi
3 Dividend Growth Stocks You Can Buy and Hold Forever
07:30am, Saturday, 26'th Oct 2024
These healthcare stocks have fantastic dividend track records.
New SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque psoriasis
08:05am, Friday, 25'th Oct 2024
First-of-its-kind Phase 3b study shows TREMFYA ® achieved statistical significance across all primary and secondary endpoints in low body surface area psoriasis with special site involvement Johnson
Two Strategic Dividend Picks: One For Dividend Income And One For Dividend Growth
06:00pm, Thursday, 24'th Oct 2024
I have added Brookfield Renewable Partners and Linde to The Dividend Income Accelerator Portfolio, increasing the portfolio's allocation to the Materials and the Utilities Sectors. After their inclusi
These 13 Stocks Are True Dividend Kings
08:49am, Thursday, 24'th Oct 2024
24/7 Wall Street Insights Dividend Kings are companies with an unbroken track record of dividend increases spanning a minimum of 50 consecutive years.
